P53和Ki-67的表达变化与三阴性乳腺癌pCR的关系研究  

Study On Relationship Between Expression of P53 and Ki-67 and pCR in Triple-Negative Breast Cancer

作　　者：傅成斌[1] 林舜国[1] 许春森[1] 韩晖[1] Fu Chengbin;Lin Shunguo;Xu Chunsen;Han Hui(Department of Breast Surgery,Union Hospital Affiliated to Fujian Medical University,Fuzhou,Fujian 350001,China)

机构地区：[1]福建医科大学附属协和医院乳腺外科,福州350001

出　　处：《河南外科学杂志》2020年第3期1-4,共4页Henan Journal of Surgery

摘　　要：目的探讨三阴性乳腺癌新辅助化疗前后P53和Ki-67的表达变化,及其与病理完全缓解率(pCR)间的关系。方法选取2016-01-2018-12间就诊的73例三阴性乳腺癌患者的病史及病理资料,均经空心针穿刺病理确诊,并接受表柔比星联合多西他赛新辅助化疗。8周期化疗后行乳腺癌改良或保乳根治术。探讨新辅助化疗前后P53和Ki-67表达变化及其与pCR间的关系。结果73例患者总体pCR为30.1%(22/73),其中P53阳性组pCR为38%(19/50)、Ki-67高表达组pCR为39.2%(20/51)、Ki-67高表达且P53阳性组pCR高达48.6%(17/35),明显高于其他组。化疗后P53阳性表达率及Ki-67表达率均明显下降,其中P53阳性组有21例转为阴性组,pCR达71.4%。结论结合化疗前后P53及Ki-67的表达变化有助于预测三阴性乳腺癌新辅助化疗的pCR。Objective To study the expression changes of P53 and Ki-67 in triple negative breast cancer before and after neoadjuvant chemotherapy, and the relationship between these changes and pathological complete response rate(pCR).Methods From January 2016 to December 2018, 73 patients with triple-negative breast cancer in our hospital were selected. All patients were confirmed by pathological diagnosis through core needle biopsy pathology, received epirubicin combined with docetaxel neoadjuvant chemotherapy. After eight cycles of chemotherapy, modified or breast-conserving radical mastectomy was performed.To study the expression of P53 and Ki-67 before and after neoadjuvant chemotherapy and their relationship with pCR.Results The total pCR of 73 triple-negative breast cancer patients was 30.1%(22/73), of which 38%(19/50) in P53 positive group, 39.2%(20/51) in Ki-67 overexpression group.The pCR in Ki-67 overexpression and P53 positive group was 48.6%(17/35), which was significantly higher than that of other groups. After chemotherapy, the positive expression rate of P53 and Ki-67 decreased significantly. 21 cases of the P53 positive patients turned negative, and the pCR of these patients reached 71.4%.Conclusion Combining the changes of P53 and Ki-67 expression before and after chemotherapy can help to predict the pCR of neoadjuvant chemotherapy in triple negative breast cancer.

关 键 词：三阴性乳腺癌 新辅助化疗 KI-67 P53 PCR 

分 类 号：R737.9[医药卫生—肿瘤]